Can a GLP-1 Drug Slow Alzheimer's? What Two Big Lancet Trials Found

Summary

Two large clinical trials found that oral semaglutide, a GLP-1 drug, did not slow memory and thinking decline in people with early Alzheimer's disease. The results, published in The Lancet in 2026, apply to people already diagnosed.

Key Takeaways

Semaglutide did not slow early Alzheimer's in two large trials.
About 3,800 people took part across 40 countries.
Lab markers shifted, but memory and daily life did not.
Common side effects were nausea, appetite loss, and weight loss.
The trials can't say if GLP-1s help prevent dementia.

You've probably seen the headlines saying GLP-1 drugs might protect the brain. It's a hopeful idea, and it's fair to ask for proof before you believe it.

Now there is real evidence to look at. Two large trials, published in The Lancet in March 2026, tested a GLP-1 pill in people with early Alzheimer's disease. [1] Here is what they found, in plain language.

Why did researchers think a GLP-1 drug might help the brain?

Earlier studies of people with type 2 diabetes linked GLP-1 drugs to a lower risk of dementia. That is why researchers wanted to test the idea directly.

GLP-1 is a natural hormone that helps your body release insulin when blood sugar rises. Semaglutide is a medicine that acts like GLP-1. It is approved for type 2 diabetes and weight management.

Some of the earlier work was observational, meaning researchers watched what happened to people over time without assigning any treatment.

One review of these studies found that GLP-1 users with type 2 diabetes had a lower rate of dementia than non-users. [2] A large real-world study found that semaglutide users had a lower risk of Alzheimer's-related dementia than people taking other diabetes medicines. [3]

Studies like these can show a link, but they can't prove cause. People who take a medicine may differ from people who don't in many other ways. Studies in mice added to the interest, because GLP-1 drugs affected inflammation and blood-vessel processes tied to Alzheimer's.

What did the two trials test?

Researchers compared a daily semaglutide pill with a placebo in about 3,800 people who had early Alzheimer's, and tracked them for two years. [1]

The two trials were named evoke and evoke+. They ran at 566 sites in 40 countries. Everyone was 55 to 85 years old and had mild memory and thinking problems or mild dementia caused by Alzheimer's. A test confirmed amyloid, a protein that builds up in Alzheimer's brains.

Each person was randomly assigned to take either semaglutide (up to 14 mg a day) or a placebo, a pill with no active drug. Neither patients nor doctors knew who got which. That is called "double-blind." People also kept getting their usual Alzheimer's care.

What were the results?

After two years, people taking semaglutide declined about the same as people taking a placebo.

The main test was a score that tracks memory, thinking, and daily function. A higher score means more decline. In both trials, the two groups ended up almost exactly the same.

Measure	Trial 1 (evoke)	Trial 2 (evoke+)	What it means
Memory-and-function score change at 2 years, semaglutide	2.3	2.2	Higher = more decline
Same score, placebo	2.3	2.1	Nearly identical to semaglutide
Everyday-activities score, difference between groups	−0.25	−0.03	No clear difference
Risk of moving from mild memory problems to mild dementia (1.0 = same risk)	0.98	0.96	About the same

Numbers come from the Lancet paper. [1]

The other tests told the same story. Researchers found no difference in other memory tests, quality of life, or mood and behavior symptoms. Results held when researchers split people by age, sex, and diabetes status.

Did anything change in the body even though symptoms didn't?

Yes. Some lab markers moved, but that did not turn into better memory or daily function. [1]

A smaller group of 199 people joined a spinal-fluid substudy. In that group, some proteins tied to Alzheimer's, and signs of inflammation and nerve-cell damage, were up to 10% lower with semaglutide than with placebo.

A blood marker of inflammation called hsCRP also dropped. Levels of it were normal at the start.

Other blood markers told a more mixed story, and researchers say they don't yet understand why.

A lab number moving is not the same as a person doing better. Here, the numbers moved and the people did not.

What were the side effects?

Side effects were mostly stomach and appetite related, and they were more common with semaglutide than with placebo. [1]

In the semaglutide group, 36.5% had weight loss reported as a side effect, versus 7.4% on placebo. About a third had decreased appetite, and nearly a quarter had nausea.

On average, people on semaglutide lost 5.8% of their body weight over two years, while the placebo group gained 0.6%.

About 17% of people on semaglutide stopped the drug because of side effects, compared with about 8% on placebo.

Serious health events were not more common with semaglutide (20.4% vs. 23.8%). The researchers reported no new safety concerns, and the side effects match what is already known for GLP-1 drugs.

Why don't these results match the earlier studies?

The trials asked a different question than the earlier studies did. The authors offer several possible reasons. [1]

Different people. Earlier studies followed people with type 2 diabetes who had no dementia symptoms when treatment started. These trials enrolled people who already had symptoms and confirmed Alzheimer's.
Different goal. Earlier studies asked who developed dementia over time. These trials asked whether decline slowed in people already diagnosed.
Lower inflammation. People in these trials had low inflammation levels at the start. People with type 2 diabetes often have higher levels.
Shorter treatment. The trials measured about two years of treatment. Some earlier studies followed people for longer.

The authors also note that semaglutide appeared to reach the brain area in only low amounts. They say treating at an earlier stage, before symptoms, might be worth studying. This trial did not test that.

What does this mean if you're curious about GLP-1s?

For people who already have early Alzheimer's, this trial found no sign that a daily GLP-1 pill slows the disease.

It tested one drug, at one dose, in one stage of disease. It does not settle whether GLP-1 drugs could help protect brain health in other groups or at other times.

That is what testing a promising idea looks like. The idea had real signals behind it, and the trial gave a clear answer.

If you take, or are thinking about taking, a GLP-1 medicine, talk with your doctor before you start, stop, or change anything. Nothing here replaces that conversation.

The Alzheimer's trials looked at one narrow question. For a wider look at GLP-1 and menopausal health, listen to this podcast episode with Stacey Littlefield.

Related read: What GLP-1 Does for You

Frequently Asked Questions regarding GLP-1 Drugs and the Brain

Does semaglutide treat Alzheimer's disease?

No. In these two large trials, it did not slow decline in people with early Alzheimer's. Semaglutide is approved for type 2 diabetes and weight management, not Alzheimer's. Both trials have since been discontinued.

Does this mean GLP-1 drugs don't protect the brain?

Not necessarily. The trials tested people who already had Alzheimer's symptoms. They did not test whether GLP-1 drugs help prevent dementia in people without symptoms. The authors say earlier-stage studies might be worth doing.

Do the results apply to weekly shots or other GLP-1 drugs?

The trials tested a daily semaglutide pill. The paper does not report results for other forms, other doses, or other GLP-1 drugs.

Who paid for the study?

Novo Nordisk, the company that makes semaglutide. The company collected and analyzed the data, and several authors work for it. An independent committee also oversaw the data, and the paper is free to read online.

What does "early-stage Alzheimer's" mean in this study?

It means mild cognitive impairment (mild memory and thinking problems) or mild dementia caused by Alzheimer's. Each person also had a positive amyloid test, from a brain scan or a spinal fluid sample.

Should I start or stop a GLP-1 medicine because of this?

This study can't answer that for you. Talk with your doctor or prescriber before you start, stop, or change any medicine.

Sources

[1] Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, Johannsen P, Wichmann CA, Abschneider RM, Leon T, Feldman HH. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167-2179. https://doi.org/10.1016/S0140-6736(26)00459-9

[2] Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S, Wu Y, Bress A, Donahoo WT, DeKosky ST, Bian J, Guo J. Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J Am Geriatr Soc. 2023;71(7):2096-2106. https://doi.org/10.1111/jgs.18306

[3] Wang W, Davis PB, Qi X, Gurney M, Perry G, Volkow ND, Kaelber DC, Xu R. Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J Alzheimers Dis. 2025;106(4):1509-1522. https://doi.org/10.1177/13872877251351329

This article is for education only. It explains published research and is not medical advice. Talk with your doctor about your own health.